Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance [scATAC]

ABSTRACT: A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance [scATAC]

PROVIDER: PRJNA725480 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14333370_1.fastq.gz	Fastqsanger.gz
	SRR14333370_2.fastq.gz	Fastqsanger.gz
	SRR14333371_1.fastq.gz	Fastqsanger.gz
	SRR14333371_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance [scATAC]

Project description:scATAC-seq datasets of immune cells in K392R and WT mice

2021-06-01 | GSE173412 | GEO

A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance

Project description:A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance

| PRJNA725474 | ENA

A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance [scRNA, scTCR]

Project description:A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance [scRNA, scTCR]

| PRJNA725479 | ENA

STAT3 secretion defect results in development abnormally

Project description:STAT3 secretion defect results in development abnormally

| PRJNA511761 | ENA

A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-06-01 | GSE173415 | GEO

A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance [scRNA, scTCR]

Project description:scRNA-seq datasets of immune cells in K392R and WT mice

2021-06-01 | GSE173413 | GEO

scATAC-seq of mouse Plasmodium-specific CD4+ T cells

Project description:Plasmodium-specific CD4+ T cells from mice infected with Plasmodium chabaudi chabaudi AS parasites were recovered at Days 0, 4, 7, and 32 to undergo processing and to generate scATAC-seq dataset. At Day 7, CXCR5+ and CXCR6+ cells were recovered separately. At Day 32, mice were administered with either saline or artesunate (intermittent artesunate therapy - IAT). scATAC-seq dataset was analysed to investigate epigenomic landscapes of CD4+ T cells from effector to memory states.

2020-10-14 | E-MTAB-9402 | biostudies-arrayexpress

ChIP-seq of Stat3 with DNA binding sites mutation in human colon cancer SW480

Project description:STAT3 is determined to play a crucial role in JAK/STAT signaling pathway. The mutations and copy number alteration of STAT3 can cause cancers and other diseases. The 317-567 amino acid domain of STAT3 protein contributes to binding with genomic DNA for gene activation. However, the impact of the mutations within DNA binding domain of STAT3 on the genomic binding pattern is not fully understood. Stat3 was deleted the 400-411 amino acid residue of \\"NNGSLSAEFKHL\\" using CRISPR-CAS9 in human colon cancer cells SW480. The cells were performed STAT3 ChIP-seq to investigate the genome-wide binding pattern of STAT3 between wild type and mutant STAT3 of SW480.

2020-07-06 | E-MTAB-8417 | biostudies-arrayexpress

scATAC-seq of early brain organoid development from pluripotency

Project description:To study developmental trajectories in brain organoids, we conducted scRNA-seq and scATAC-seq in parallel on a dense timecourse of early development.

2022-08-18 | E-MTAB-11998 | biostudies-arrayexpress

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Project description:Many patients have cancers that have increased activity of a protein called STAT3 that contributes critically to the development and growth of their cancer. Despite our knowledge of STAT3’s importance to cancer, scientists and doctors have not developed a drug that targets it and that patients can take to treat their cancer more effectively than treatments that are now available. Tvardi Therapeutics, Incorporated has developed a compound, TTI-101, which can be given by mouth and acts as a direct inhibitor of STAT3. Administration of TTI-101 to mice demonstrated that it blocked growth of cancers of the breast, head and neck, lung, and liver and it was safe when administered at high doses to mice, rats, and dogs. In this application, Tvardi is proposing to further develop TTI-101 for treatment of solid tumors for which the prognosis is dismal. The investigators will determine how safe it is when administered to patients with cancer, determine whether an adequate dose can be administered to patients with cancer that will block STAT3 in their cancer, and determine whether treatment with TTI-101 leads to reduced growth of their cancer.

| 2247646 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data